BioSpace Interviews Penn Spinout Leaders About Life Sciences Growth in Philadelphia
In an article by BioSpace, Philadelphia is showcased as a major life sciences hub.
Penn Dental Medicine, Penn Medicine and Penn Engineering Identify Nanoparticles that May Offer an Alternative Treatment Option for Root Canals
Researchers identified ferumoxytol, an FDA-approved iron oxide nanoparticle, as a highly effective alternative to traditional root canal disinfectants.
Gynuin Accepted into the LifeX Accelerator
Gynuin is focused on developing a medical device to secure immediate postpartum IUDs and prevent unintended pregnancies and complications.
Penn Spinout Verismo Doses First Patient withSynKIR-310 Treatment
This therapy has the potential to prolong T-cell persistence to combat disease relapse.
GEMMABio and Sahay AI Make Technical.ly Philly’s RealLIST of Up-and-Coming Startups
Technical.ly’s annual RealLIST Startups identifies the top young companies in the Philadelphia region who are on track to continue their momentum.
Every Cure Uses AI Tool to Match Patients with Medications
David Fajgenbaum led a team that developed artificial intelligence powered technology that matches rare diseases with existing medications.
Berger Lab Makes Discovery Linking cellular structures to kidney cancer treatment outcomes
These findings could pave the way for personalized treatments, matching patients to drugs based on their tumor's speckle pattern.
iECURE Reports on Preliminary Clinical Response Data in First Infant Dosed with its in vivo Gene Editing Candidate ECUR-506
iECURE reported preliminary findings from the first infant dosed with its in vivo gene editing candidate ECUR-506.
ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy
ViTToria has dosed the first patient in its Phase 1 clinical trial for VIPER-101.
āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.